Skip to main content

Table 1 Baseline characteristics

From: Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer

  HLA-A*24:02 HLA-A*24:02 p-value
matched unmatched
Number of patients 36 27  
Age, years 62.9 ± 2.1 63.4 ± 2.1 0.7072
Gender    0.3074
 Male 17 (47.2%) 17 (63.0%)  
 Female 19 (52.8%) 10 (37.0%)  
Stage (UICC)    0.7439
 III 7 (19.4%) 5 (18.5%)  
 IV 26 (72.2%) 21 (77.8%)  
 Recurrence 3 (8.3%) 1 (3.7%)  
Tumor marker    
 CEA 369.2 ± 247.9 8.5 ± 2.1 0.1722
 CA19-9 3870.1 ± 1972.7 3643.2 ± 1444.7 0.0718
  1. Abbreviations: HLA human leukocyte antigen, UICC Union for International Cancer Control, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9